E 6123

platelet activating factor antagonist

Also Known As:

6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido(4',3'-4,5)-thieno-(3,2-f)-1,2,4-triazolo(4,3-a)(1,4)diazepine; E-6123; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (S)-

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - E 6123: 3
  - Azepines: 11
    - E 6123: 3

Related Diseases

1.	Pruritus (Itching) 02/01/1995 - "Thus PAF-induced ocular pruritus was unaffected by the histamine H1-receptor antagonist pyrilamine but was substantially attenuated by the PAF antagonists WEB 2086 and CV-6209 and was virtually abolished by E-6123. "
2.	Nephrosis 12/01/1991 - "E-6123 reversed PAF and/or endotoxin injection-induced hypotension in rats after intravenous administration at 3 micrograms/kg. The increase in urinary protein excretion of rats in which nephrosis had been induced by intraperitoneal injection of aminonucleoside was not inhibited by oral administration of E-6123 at 10 mg/kg/d."
3.	Edema (Dropsy) 12/01/1991 - "E-6123 inhibited PAF injection-induced microvascular permeability (edema) in guinea pigs after oral administration at 3 micrograms/kg. The inhibitory effects of E-6123 were very potent compared to those of other PAF antagonists. "
4.	Asthma (Bronchial Asthma) 03/01/1991 - "The results also suggest that E-6123 may be of therapeutic value in the treatment of asthma exhibiting eosinophil recruitment in airways."

Related Drugs and Biologics

1.	Pyrilamine (Mepyramine)
2.	Puromycin Aminonucleoside
3.	Proteins (Proteins, Gene)
4.	Histamine (Histamine Dihydrochloride)
5.	Endotoxins
6.	Dihydrotachysterol (AT 10)
7.	CV 6209
8.	WEB 2086 (apafant)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Intraperitoneal Injections
3.	Controlled Hypotension
4.	Oral Administration